Overview

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S